Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Retreatment with immune checkpoint inhibitors (ICIs) might be a subsequent therapeutic option for patients with non-small cell lung cancer (NSCLC) who discontinued initial ICIs treatment because of disease progression, immune-related adverse events (irAEs) or completion of a fixed course...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Zijing, Zhan, Ping, Song, Yong, Liu, Hongbing, Lv, Tangfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459604/
https://www.ncbi.nlm.nih.gov/pubmed/36090645
http://dx.doi.org/10.21037/tlcr-22-140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459604/
https://www.ncbi.nlm.nih.gov/pubmed/36090645
http://dx.doi.org/10.21037/tlcr-22-140

Ejemplares similares